The South Korean government is introducing its first "testbed" program to validate medical artificial intelligence technologies in actual hospital settings. The initiative aims to move medical AI from the laboratory stage into clinical environments, verify its effectiveness and safety, and support its path to commercialization.
The Ministry of Health and Welfare (MOHW) and the Korea Health Information Service announced Wednesday that they will accept applications for consortia to participate in the "2026 Medical AI Testbed Support Program" from March 31 through May 4. Medical data-centered hospitals and small and medium-sized medical AI companies will form teams to participate.
Selected consortia will receive up to 400 million won ($290,000) per project in validation funding. A total of 22 projects will be selected across two categories: AI-based diagnostic and predictive digital medical devices (Type 1), and non-medical device AI for clinical record automation and hospital operational efficiency (Type 2).
The core of the program is "validation in real hospital environments." Medical AI cannot be judged on accuracy alone — its impact on patient safety and treatment outcomes must also be confirmed. The government has therefore designed a framework that goes beyond simple performance evaluation to simultaneously verify clinical efficacy and cost-effectiveness.
A notable feature is that validation will be conducted through medical data-centered hospitals. Currently 45 hospitals participate in the program, which has the advantage of established clinical data infrastructure, enabling AI solutions to be integrated with and evaluated within actual clinical systems.
The government expects the program to accelerate market entry for the medical AI industry. Officials believe it can overcome the longstanding gap between technology development and hospital adoption, serving as a catalyst for commercialization.
"Since medical AI is directly linked to patient safety, validation in real clinical settings is essential," a MOHW official stressed. "We will support the adoption of products whose clinical value has been proven through collaboration between hospitals and companies."
